SLC5A2 and hydrops fetalis: Additional support for the therapeutic potential of SGLT2 inhibitors in AS comes from the EASTER-HF study [119], a retrospective observational analysis evaluating the role of empagliflozin in patients with severe degenerative AS (DAS) and HF prior to AVR.